Prodrug specialist reveals positive topline data for ADHD candidate

10 July 2018

Iowa, USA-based specialty drugmaker KemPharm (Nasdaq: KMPH) says a key pivotal trial of its lead candidate, an investigational attention-deficit/hyperactivity disorder (ADHD) product, met the primary and secondary efficacy endpoint.

The trial is evaluating KP415, which contains a compound called d-methylphenidate and one of its prodrugs, in patients aged 6-12. Topline results show a statistically-significant improvement according to several commonly used measures of ADHD symptoms.

Chief executive Travis Mickle said: “We anticipate developing additional clinical data for KP415 throughout 2018, including the completion of our ongoing oral and intranasal Human Abuse Potential studies.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK